HomeBUSINESS
BUSINESS

Can Japan’s 1st Enbrel Biosimilar Make Its Mark in RA Follow-On Arena with Self-Injection?
(Nov.10.2017)

The arrival of Japan’s first Enbrel (etanercept) biosimilar is drawing near. The biosimilar of Mochida Pharmaceutical will likely reach the market soon after its expected listing in May next year. Mochida Executive Managing Director Junichi Sakaki says the company projects billions of yen in peak sales of the product, which will be mainly sold by rheumatoid arthritis (RA)-savvy partner Ayumi Pharmaceutical ...
(LOG IN FOR FULL STORY)

News Calendar